{"&cites=13898631485117911629&as_sdt=2005&sciodt=0,5&hl=en":[{"title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816714","authors":["BI Rini","BI Rini ER Plimack","BI Rini ER Plimack V Stus","BI Rini ER Plimack V Stus R Gafanov…"],"year":2019,"numCitations":545,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816714","citationUrl":"http://scholar.google.com/scholar?cites=14370914940926626173&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:fQlJl_--b8cJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=14370914940926626173&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc","p":1,"exp":1596898395883},{"title":"Fundamental mechanisms of immune checkpoint blockade therapy","url":"https://cancerdiscovery.aacrjournals.org/content/8/9/1069.abstract","authors":["SC Wei","SC Wei CR Duffy","SC Wei CR Duffy JP Allison"],"year":2018,"numCitations":534,"pdf":"https://cancerdiscovery.aacrjournals.org/content/candisc/8/9/1069.full.pdf","citationUrl":"http://scholar.google.com/scholar?cites=2653008792991623793&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:cepA5HBh0SQJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=2653008792991623793&hl=en&as_sdt=2005&sciodt=0,5","publication":"AACR"},{"title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816047","authors":["RJ Motzer","RJ Motzer K Penkov","RJ Motzer K Penkov J Haanen","RJ Motzer K Penkov J Haanen B Rini…"],"year":2019,"numCitations":502,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816047","citationUrl":"http://scholar.google.com/scholar?cites=1882792696390332365&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:za8LXvsFIRoJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1882792696390332365&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","url":"https://jamanetwork.com/journals/jamaoncology/article-abstract/2701721","authors":["DY Wang","DY Wang JE Salem","DY Wang JE Salem JV Cohen","DY Wang JE Salem JV Cohen S Chandra…"],"year":2018,"numCitations":365,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440712/","citationUrl":"http://scholar.google.com/scholar?cites=13897680576669842543&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:b3xA9tl63sAJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=13897680576669842543&hl=en&as_sdt=2005&sciodt=0,5","publication":"jamanetwork.com"},{"title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1803675","authors":["A Méjean","A Méjean A Ravaud","A Méjean A Ravaud S Thezenas…"],"year":2018,"numCitations":332,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1803675","citationUrl":"http://scholar.google.com/scholar?cites=2759106540828352675&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:o-CHz8dQSiYJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=2759106540828352675&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","url":"https://www.nature.com/articles/s41591-018-0053-3?sf191006923=1","authors":["DF McDermott","DF McDermott MA Huseni","DF McDermott MA Huseni MB Atkins","DF McDermott MA Huseni MB Atkins RJ Motzer…"],"year":2018,"numCitations":270,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6721896/","citationUrl":"http://scholar.google.com/scholar?cites=14003279356171476270&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:Ll0pw2GkVcIJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=14003279356171476270&hl=en&as_sdt=2005&sciodt=0,5","publication":"nature.com"},{"title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","url":"https://www.nature.com/articles/s41573-018-0007-y","authors":["J Galon","J Galon D Bruni"],"year":2019,"numCitations":277,"pdf":"https://file.zhisci.com/upload_oss%2Fpdf%2F2019%2F0001%2F201900017185-cn.pdf","citationUrl":"http://scholar.google.com/scholar?cites=1493736680934419863&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:ly0R35jRuhQJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1493736680934419863&hl=en&as_sdt=2005&sciodt=0,5","publication":"nature.com"},{"title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","url":"https://www.sciencedirect.com/science/article/pii/S1567576918302522","authors":["KM Hargadon","KM Hargadon CE Johnson","KM Hargadon CE Johnson CJ Williams"],"year":2018,"numCitations":205,"citationUrl":"http://scholar.google.com/scholar?cites=12077726576977769779&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:M_UNy1S0nKcJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=12077726576977769779&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"}]}